Adult immunization schedule
CDC adult schedule · addendum updated July 2, 2025 · matches CDC's live page, re-checked 12 Oct 2026 · About this view
19-26 years
Where CDC's chart changes category inside an age group, a vaccine appears under each category and is marked as part of the group.
Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity
- COVID-19
1 or more doses of 2024–2025 vaccine (See Notes)
RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19 - Influenza inactivated (IIV3, ccIIV3)
Influenza recombinant (RIV3)1 dose annually
- Influenza live, attenuated (LAIV3)
1 dose annually
- Tetanus, diphtheria, pertussis
(Tdap or Td)1 dose Tdap, then Td or Tdap booster every 10 years
- Measles, mumps, rubella
(MMR)1 or 2 doses depending on indication
(if born in 1957 or later) - Varicella
(VAR)2 doses (if born in 1980 or later)
- Human papillomavirus
(HPV)2 or 3 doses depending on age at initial vaccination or condition
- Hepatitis B
(HepB)2, 3, or 4 doses depending on vaccine or condition
- Inactivated poliovirus
(IPV)Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Recommended vaccination for adults with an additional risk factor or another indication
- Influenza inactivated
(aIIV3; HD–IIV3)
Influenza recombinant (RIV3)Solid organ transplant (See Notes)
- Respiratory Syncytial Virus
(RSV)Seasonal administration during pregnancy.
(See Notes)
- Tetanus, diphtheria, pertussis
(Tdap or Td)1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (See Notes)
- Zoster recombinant
(RZV)2 doses for immunocompromising conditions
(See Notes) - Pneumococcal
(PCV15, PCV20,PCV21, PPSV23)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Hepatitis A
(HepA)2, 3, or 4 doses depending on vaccine
- Meningococcal A, C, W, Y
(MenACWY)1 or 2 doses depending on indication (See Notes for booster recommendations)
- Meningococcal B
(MenB)2 or 3 doses depending on vaccine and indication (See Notes for booster recommendations)
CDC's chart shows this for part of this age group. - Haemophilus influenzae type b
(Hib)1 or 3 doses depending on indication
- Mpox
2 doses
Recommended vaccination based on shared clinical decision-making
- Meningococcal B
(MenB)19 through 23 years
CDC's chart shows this for part of this age group.
27-49 years
Where CDC's chart changes category inside an age group, a vaccine appears under each category and is marked as part of the group.
Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity
- COVID-19
1 or more doses of 2024–2025 vaccine (See Notes)
RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19 - Influenza inactivated (IIV3, ccIIV3)
Influenza recombinant (RIV3)1 dose annually
- Influenza live, attenuated (LAIV3)
1 dose annually
- Tetanus, diphtheria, pertussis
(Tdap or Td)1 dose Tdap, then Td or Tdap booster every 10 years
- Measles, mumps, rubella
(MMR)1 or 2 doses depending on indication
(if born in 1957 or later) - Varicella
(VAR)2 doses (if born in 1980 or later)
CDC's chart shows this for part of this age group. - Hepatitis B
(HepB)2, 3, or 4 doses depending on vaccine or condition
- Inactivated poliovirus
(IPV)Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Recommended vaccination for adults with an additional risk factor or another indication
- Influenza inactivated
(aIIV3; HD–IIV3)
Influenza recombinant (RIV3)Solid organ transplant (See Notes)
- Respiratory Syncytial Virus
(RSV)Seasonal administration during pregnancy.
(See Notes)
- Tetanus, diphtheria, pertussis
(Tdap or Td)1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (See Notes)
- Varicella
(VAR)2 doses
CDC's chart shows this for part of this age group. - Zoster recombinant
(RZV)2 doses for immunocompromising conditions
(See Notes) - Pneumococcal
(PCV15, PCV20,PCV21, PPSV23)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Hepatitis A
(HepA)2, 3, or 4 doses depending on vaccine
- Meningococcal A, C, W, Y
(MenACWY)1 or 2 doses depending on indication (See Notes for booster recommendations)
- Meningococcal B
(MenB)2 or 3 doses depending on vaccine and indication (See Notes for booster recommendations)
- Haemophilus influenzae type b
(Hib)1 or 3 doses depending on indication
- Mpox
2 doses
Recommended vaccination based on shared clinical decision-making
- Human papillomavirus
(HPV)27 through 45 years
CDC's chart shows this for part of this age group.
No Guidance/Not Applicable
Human papillomavirus (HPV)
50-64 years
Where CDC's chart changes category inside an age group, a vaccine appears under each category and is marked as part of the group.
Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity
- COVID-19
1 or more doses of 2024–2025 vaccine (See Notes)
RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19 - Influenza inactivated (IIV3, ccIIV3)
Influenza recombinant (RIV3)1 dose annually
- Tetanus, diphtheria, pertussis
(Tdap or Td)1 dose Tdap, then Td or Tdap booster every 10 years
- Measles, mumps, rubella
(MMR)1 or 2 doses depending on indication
(if born in 1957 or later) - Zoster recombinant
(RZV)2 doses
- Pneumococcal
(PCV15, PCV20,PCV21, PPSV23)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Hepatitis B
(HepB)2, 3, or 4 doses depending on vaccine or condition
CDC's chart shows this for part of this age group. - Inactivated poliovirus
(IPV)Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Recommended vaccination for adults with an additional risk factor or another indication
- Influenza inactivated
(aIIV3; HD–IIV3)
Influenza recombinant (RIV3)Solid organ transplant (See Notes)
- Respiratory Syncytial Virus
(RSV)50 through 74 years (See Notes)
- Tetanus, diphtheria, pertussis
(Tdap or Td)1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (See Notes)
- Varicella
(VAR)2 doses
- Hepatitis A
(HepA)2, 3, or 4 doses depending on vaccine
- Hepatitis B
(HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group. - Meningococcal A, C, W, Y
(MenACWY)1 or 2 doses depending on indication (See Notes for booster recommendations)
- Meningococcal B
(MenB)2 or 3 doses depending on vaccine and indication (See Notes for booster recommendations)
- Haemophilus influenzae type b
(Hib)1 or 3 doses depending on indication
- Mpox
2 doses
No Guidance/Not Applicable
Influenza live, attenuated (LAIV3) · Human papillomavirus (HPV)
≥65 years
Where CDC's chart changes category inside an age group, a vaccine appears under each category and is marked as part of the group.
Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity
- COVID-19
2 or more doses of 2024-2025 vaccine
RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
(See Notes) - Influenza inactivated (IIV3, ccIIV3)
Influenza recombinant (RIV3)1 dose annually
(HD–IIV3, RIV3, or aIIV3 preferred) - Influenza inactivated
(aIIV3; HD–IIV3)
Influenza recombinant (RIV3)1 dose annually
(HD–IIV3, RIV3, or aIIV3 preferred) - Respiratory Syncytial Virus
(RSV)≥75 years
CDC's chart shows this for part of this age group. - Tetanus, diphtheria, pertussis
(Tdap or Td)1 dose Tdap, then Td or Tdap booster every 10 years
- Measles, mumps, rubella
(MMR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group. - Zoster recombinant
(RZV)2 doses
- Pneumococcal
(PCV15, PCV20,PCV21, PPSV23)See Notes
- Inactivated poliovirus
(IPV)Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Recommended vaccination for adults with an additional risk factor or another indication
- Respiratory Syncytial Virus
(RSV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group. - Tetanus, diphtheria, pertussis
(Tdap or Td)1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (See Notes)
- Varicella
(VAR)2 doses
- Hepatitis A
(HepA)2, 3, or 4 doses depending on vaccine
- Hepatitis B
(HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Meningococcal A, C, W, Y
(MenACWY)1 or 2 doses depending on indication (See Notes for booster recommendations)
- Meningococcal B
(MenB)2 or 3 doses depending on vaccine and indication (See Notes for booster recommendations)
- Haemophilus influenzae type b
(Hib)1 or 3 doses depending on indication
- Mpox
2 doses
Recommended vaccination based on shared clinical decision-making
- Pneumococcal
(PCV15, PCV20,PCV21, PPSV23)See Notes
No Guidance/Not Applicable
Influenza live, attenuated (LAIV3) · Measles, mumps, rubella (MMR) · Human papillomavirus (HPV)
Pregnancy
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- Influenza inactivated
Influenza recombinant CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - RSV
Seasonal administration. (See Notes)
- HepB
See Notes
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes.
Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction
Contraindicated or not recommended *Vaccinate after pregnancy, if indicated
No Guidance/Not Applicable
COVID-19 · RZV · Pneumococcal · MenACWY · Hib
Immuno-compromised (excluding HIV infection)
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- Influenza inactivated
Influenza recombinantSolid organ transplant
(See Notes) - Tdap or Td
1 dose Tdap, then Td or Tdap booster every 10 yrs
- RZV
See Notes
- PneumococcalCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- IPV
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes.
- COVID-19
See Notes
RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19 - Hib
HSCT: 3 dosesc
Contraindicated or not recommended *Vaccinate after pregnancy, if indicated
HIV infection CD4 percentage and count – <15% or <200/mm3
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- Influenza inactivated
Influenza recombinant1 dose annually
- Tdap or Td
1 dose Tdap, then Td or Tdap booster every 10 yrs
- RZV
See Notes
- PneumococcalCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepACDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepBCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- IPV
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes.
- COVID-19
See Notes
RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19 - MenACWYCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Contraindicated or not recommended *Vaccinate after pregnancy, if indicated
HIV infection CD4 percentage and count – ≥15% and ≥200/mm3
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- COVID-19CDC's chart shows this category here without further text; see CDC's notes for this vaccine.RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
- Influenza inactivated
Influenza recombinant1 dose annually
- Tdap or Td
1 dose Tdap, then Td or Tdap booster every 10 yrs
- MMRCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- VAR
See Notes
- RZV
See Notes
- PneumococcalCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepACDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepBCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- IPV
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes.
- MenACWYCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Contraindicated or not recommended *Vaccinate after pregnancy, if indicated
- LAIV3CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Men who have sex with men
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- COVID-19CDC's chart shows this category here without further text; see CDC's notes for this vaccine.RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
- Influenza inactivated
Influenza recombinant1 dose annually
- Tdap or Td
1 dose Tdap, then Td or Tdap booster every 10 yrs
- MMRCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- VARCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepACDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepBCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- IPV
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
- LAIV3
1 dose annually if age
19–49 years - RSVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- RZVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HPVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- PneumococcalCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Mpox
See Notes
Asplenia, complement deficiency
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- COVID-19CDC's chart shows this category here without further text; see CDC's notes for this vaccine.RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
- Influenza inactivated
Influenza recombinant1 dose annually
- Tdap or Td
1 dose Tdap, then Td or Tdap booster every 10 yrs
- MMRCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- VARCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- PneumococcalCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Hib
Asplenia:
1 dose - IPV
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
- RSV
See Notes
- RZVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HPVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepBCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- MpoxCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes.
Contraindicated or not recommended *Vaccinate after pregnancy, if indicated
- LAIV3CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
No Guidance/Not Applicable
Heart or lung disease
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- COVID-19CDC's chart shows this category here without further text; see CDC's notes for this vaccine.RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
- Influenza inactivated
Influenza recombinant1 dose annually
- Tdap or Td
1 dose Tdap, then Td or Tdap booster every 10 yrs
- MMRCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- VARCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- PneumococcalCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- IPV
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
- RSV
See Notes
- RZVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HPVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepBCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- MpoxCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction
- LAIV3
1 dose annually if age 19–
Kidney failure, End-stage renal disease or on dialysis
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- COVID-19CDC's chart shows this category here without further text; see CDC's notes for this vaccine.RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
- Influenza inactivated
Influenza recombinant1 dose annually
- Tdap or Td
1 dose Tdap, then Td or Tdap booster every 10 yrs
- MMRCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- VARCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- PneumococcalCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepBCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- IPV
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction
- LAIV3
1 dose annually if age 19–
Chronic liver disease; alcoholisma
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- COVID-19CDC's chart shows this category here without further text; see CDC's notes for this vaccine.RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
- Influenza inactivated
Influenza recombinant1 dose annually
- Tdap or Td
1 dose Tdap, then Td or Tdap booster every 10 yrs
- MMRCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- VARCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- PneumococcalCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepACDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepBCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- IPV
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
- RSV
Liver disease
(See Notes) - RZVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HPVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- MpoxCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction
- LAIV3
1 dose annually if age 19–
Diabetes
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- COVID-19CDC's chart shows this category here without further text; see CDC's notes for this vaccine.RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
- Influenza inactivated
Influenza recombinant1 dose annually
- Tdap or Td
1 dose Tdap, then Td or Tdap booster every 10 yrs
- MMRCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- VARCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- PneumococcalCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepBCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- IPV
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
Recommended based on shared clinical decision-making
- HepB
Age
≥ 60 years
Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction
- LAIV3
1 dose annually if age 19–
Health care Personnelb
Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- COVID-19CDC's chart shows this category here without further text; see CDC's notes for this vaccine.RxEvidence note: CDC's adult schedule tables and notes (addendum updated July 2, 2025) name 2024–2025 COVID-19 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines and to individual-based decision-making. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
- Influenza inactivated
Influenza recombinant1 dose annually
- Tdap or Td
1 dose Tdap, then Td or Tdap booster every 10 yrs
- MMRCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- VARCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HepBCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- IPV
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes)
Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
- LAIV3
49 years
- RSVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- RZVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- HPVCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- PneumococcalCDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Mpox
See Notes
CDC's footnotes for this table
- Precaution for LAIV4 does not apply to alcoholism.
- See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations.
- Hematopoietic stem cell transplant.
About this view
Each entry is CDC's own cell text from its adult schedule, regrouped column by column; the headings are CDC's own legend wording. RxEvidence has not added, removed or reworded schedule content. Read it with CDC's notes, which hold dose intervals and conditions. Source: CDC, adult schedule by age. Source: CDC, adult schedule by medical condition or other indication. The same tables as CDC draws them, with every column side by side, are on the schedules page.
The re-check date means this copy was compared with CDC's live page and was identical; it does not mean CDC's page is current for every product or season.
Show CDC's full adult chart by age, all age groups side by side (scrolls sideways)
Adult immunization schedule by age
Source: CDC, Adult immunization schedule by age. Each cell is CDC's own wording. CDC's page shows: addendum updated July 2, 2025. Re-checked against CDC's live page on 12 Oct 2026: the tables are identical. These tables must be read with CDC's notes, which hold the dose intervals and catch-up rules. A vaccine's name links to CDC's notes for it.
- Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity
- Recommended vaccination for adults with an additional risk factor or another indication
- Recommended vaccination based on shared clinical decision-making
- No Guidance/Not Applicable
Scroll sideways to see every age. Colour is never the only signal: hover or focus a cell for CDC's wording of what it means.
Ages 19 Years or Older
| Vaccine | 19-26 years | 27-49 years | 50-64 years | ≥65 years | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19 | 1 or more doses of 2024–2025 vaccine (See Notes) | 2 or more doses of 2024-2025 vaccine (See Notes) | ||||||||||
| Influenza inactivated (IIV3, ccIIV3) Influenza recombinant (RIV3) | 1 dose annually | 1 dose annually (HD–IIV3, RIV3, or aIIV3 preferred) | ||||||||||
| Influenza inactivated (aIIV3; HD–IIV3) Influenza recombinant (RIV3) | Solid organ transplant (See Notes) | |||||||||||
| Influenza live, attenuated (LAIV3) | 1 dose annually | No Guidance/Not Applicable | ||||||||||
| Respiratory Syncytial Virus (RSV) | Seasonal administration during pregnancy. (See Notes) | 50 through 74 years (See Notes) | Recommended vaccination for adults with an additional risk factor or another indication. | ≥75 years | ||||||||
| Tetanus, diphtheria, pertussis (Tdap or Td) | 1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (See Notes) | |||||||||||
| 1 dose Tdap, then Td or Tdap booster every 10 years | ||||||||||||
| Measles, mumps, rubella (MMR) | 1 or 2 doses depending on indication (if born in 1957 or later) | Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity | For health care personnel, (See Notes) | No Guidance/Not Applicable | ||||||||
| Varicella (VAR) | 2 doses (if born in 1980 or later) | Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity | Recommended vaccination for adults with an additional risk factor or another indication. | 2 doses | ||||||||
| Zoster recombinant (RZV) | 2 doses for immunocompromising conditions (See Notes) | 2 doses | ||||||||||
| Human papillomavirus (HPV) | 2 or 3 doses depending on age at initial vaccination or condition | 27 through 45 years | Recommended vaccination based on shared clinical decision-making | No Guidance/Not Applicable | No Guidance/Not Applicable | No Guidance/Not Applicable | ||||||
| Pneumococcal (PCV15, PCV20,PCV21, PPSV23) | Recommended vaccination for adults with an additional risk factor or another indication | Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity | See Notes | |||||||||
| See Notes | ||||||||||||
| Hepatitis A (HepA) | 2, 3, or 4 doses depending on vaccine | |||||||||||
| Hepatitis B (HepB) | 2, 3, or 4 doses depending on vaccine or condition | Recommended vaccination for adults with an additional risk factor or another indication. | ||||||||||
| Meningococcal A, C, W, Y (MenACWY) | 1 or 2 doses depending on indication (See Notes for booster recommendations) | |||||||||||
| Meningococcal B (MenB) | Recommended vaccination for adults with an additional risk factor or another indication | 2 or 3 doses depending on vaccine and indication (See Notes for booster recommendations) | ||||||||||
| 19 through 23 years | Recommended vaccination for adults with an additional risk factor or another indication | Recommended vaccination for adults with an additional risk factor or another indication | ||||||||||
| Haemophilus influenzae type b (Hib) | 1 or 3 doses depending on indication | |||||||||||
| Mpox | 2 doses | |||||||||||
| Inactivated poliovirus (IPV) | Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes) | |||||||||||
Show CDC's full adult chart by medical condition (scrolls sideways)
Adult immunization schedule by medical condition or other indication
Source: CDC, Adult immunization schedule by medical condition or other indication. Each cell is CDC's own wording. CDC's page shows: addendum updated July 2, 2025. Re-checked against CDC's live page on 12 Oct 2026: the tables are identical. These tables must be read with CDC's notes, which hold the dose intervals and catch-up rules. A vaccine's name links to CDC's notes for it.
- Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity
- Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease
- Recommended based on shared clinical decision-making
- Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes.
- Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction
- Contraindicated or not recommended *Vaccinate after pregnancy, if indicated
- No Guidance/Not Applicable
Scroll sideways to see every age. Colour is never the only signal: hover or focus a cell for CDC's wording of what it means.
Ages 19 Years or Older
| Vaccine | Pregnancy | Immuno-compromised (excluding HIV infection) | HIV infection CD4 percentage and count | Men who have sex with men | Asplenia, complement deficiency | Heart or lung disease | Kidney failure, End-stage renal disease or on dialysis | Chronic liver disease; alcoholisma | Diabetes | Health care Personnelb | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <15% or <200/mm3 | ≥15% and ≥200/mm3 | ||||||||||
| COVID-19 | No Guidance/Not Applicable | See Notes | Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity | ||||||||
| Influenza inactivated Influenza recombinant | Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity | Solid organ transplant (See Notes) | 1 dose annually | ||||||||
| LAIV3 | Contraindicated or not recommended *Vaccinate after pregnancy, if indicated | 1 dose annually if age 19–49 years | Contraindicated or not recommended *Vaccinate after pregnancy, if indicated | 1 dose annually if age 19– | 49 years | ||||||
| RSV | Seasonal administration. (See Notes) | See Notes | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | See Notes | Liver disease (See Notes) | See Notes | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | ||||
| Tdap or Td | Tdap: 1 dose each pregnancy | 1 dose Tdap, then Td or Tdap booster every 10 yrs | |||||||||
| MMR | * | Contraindicated or not recommended *Vaccinate after pregnancy, if indicated | Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity | ||||||||
| VAR | * | Contraindicated or not recommended *Vaccinate after pregnancy, if indicated | See Notes | Recommended for all adults who lack documentation of vaccination, OR lack evidence of past infection | |||||||
| RZV | No Guidance/Not Applicable | See Notes | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | ||||||||
| HPV | * | 3-dose series if indicated | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | ||||||||
| Pneumococcal | No Guidance/Not Applicable | Recommended for all adults who lack documentation of vaccination, OR lack evidence of past infection | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | Recommended for all adults who lack documentation of vaccination, OR lack evidence of past infection | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | ||||||
| HepA | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | No Guidance/Not Applicable | Recommended for all adults who lack documentation of vaccination, OR lack evidence of past infection | No Guidance/Not Applicable | Recommended for all adults who lack documentation of vaccination, OR lack evidence of past infection | No Guidance/Not Applicable | |||||
| HepB | See Notes | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | Recommended for all adults who lack documentation of vaccination, OR lack evidence of past infection | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | Recommended for all adults who lack documentation of vaccination, OR lack evidence of past infection | Recommended for all adults who lack documentation of vaccination, OR lack evidence of past infection | Recommended for all adults who lack documentation of vaccination, OR lack evidence of past infection | ||||
| Age ≥ 60 years | |||||||||||
| MenACWY | No Guidance/Not Applicable | Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes. | No Guidance/Not Applicable | Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes. | No Guidance/Not Applicable | ||||||
| MenB | Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction | No Guidance/Not Applicable | Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes. | No Guidance/Not Applicable | |||||||
| Hib | No Guidance/Not Applicable | HSCT: 3 dosesc | No Guidance/Not Applicable | Asplenia: 1 dose | No Guidance/Not Applicable | ||||||
| Mpox | See Notes | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | See Notes | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | See Notes | ||||||
| IPV | Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction | Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes) | |||||||||
CDC's footnotes for this table
- Precaution for LAIV4 does not apply to alcoholism.
- See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations.
- Hematopoietic stem cell transplant.
Child and adolescent immunization schedule
CDC child and adolescent schedule · addendum updated July 2, 2025 · matches CDC's live page, re-checked 12 Oct 2026 · About this view
Birth to 15 Months
18 Months to 18 Years
Birth to 15 Months: Birth
Range of recommended ages for all children
- Respiratory syncytial virus
(RSV-mAb [Nirsevimab])1 dose depending on maternal RSV vaccination status, See Notes
- Hepatitis B
(HepB)1st dose
No Guidance/Not Applicable
Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) · Haemophilus influenzae type b (Hib) · Pneumococcal conjugate (PCV15, PCV20) · Inactivated poliovirus (IPV) · COVID-19 (1vCOV-mRNA, 1vCOV-aPS) · Influenza (IIV3, ccIIV3) · Influenza (LAIV3) · Measles, mumps, rubella (MMR) · Varicella (VAR) · Hepatitis A (HepA) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9-16 yrs) · Mpox
Birth to 15 Months: 1 mo
Range of recommended ages for all children
- Respiratory syncytial virus
(RSV-mAb [Nirsevimab])1 dose depending on maternal RSV vaccination status, See Notes
- Hepatitis B
(HepB)←2nd dose→
No Guidance/Not Applicable
Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) · Haemophilus influenzae type b (Hib) · Pneumococcal conjugate (PCV15, PCV20) · Inactivated poliovirus (IPV) · COVID-19 (1vCOV-mRNA, 1vCOV-aPS) · Influenza (IIV3, ccIIV3) · Influenza (LAIV3) · Measles, mumps, rubella (MMR) · Varicella (VAR) · Hepatitis A (HepA) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9-16 yrs) · Mpox
Birth to 15 Months: 2 mos
Range of recommended ages for all children
- Respiratory syncytial virus
(RSV-mAb [Nirsevimab])1 dose depending on maternal RSV vaccination status, See Notes
- Hepatitis B
(HepB)←2nd dose→
- Rotavirus (RV)
RV1 (2-dose series); RV5 (3-dose series)1st dose
- Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs)1st dose
- Haemophilus influenzae type b
(Hib)1st dose
- Pneumococcal conjugate
(PCV15, PCV20)1st dose
- Inactivated poliovirus
(IPV)1st dose
Range of recommended ages for certain high-risk groups or populations
- Meningococcal
(MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)See Notes
No Guidance/Not Applicable
COVID-19 (1vCOV-mRNA, 1vCOV-aPS) · Influenza (IIV3, ccIIV3) · Influenza (LAIV3) · Measles, mumps, rubella (MMR) · Varicella (VAR) · Hepatitis A (HepA) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9-16 yrs) · Mpox
Birth to 15 Months: 4 mos
Range of recommended ages for all children
- Respiratory syncytial virus
(RSV-mAb [Nirsevimab])1 dose depending on maternal RSV vaccination status, See Notes
- Rotavirus (RV)
RV1 (2-dose series); RV5 (3-dose series)2nd dose
- Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs)2nd dose
- Haemophilus influenzae type b
(Hib)2nd dose
- Pneumococcal conjugate
(PCV15, PCV20)2nd dose
- Inactivated poliovirus
(IPV)2nd dose
Range of recommended ages for catch-up vaccination
- Hepatitis B
(HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Meningococcal
(MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)See Notes
No Guidance/Not Applicable
COVID-19 (1vCOV-mRNA, 1vCOV-aPS) · Influenza (IIV3, ccIIV3) · Influenza (LAIV3) · Measles, mumps, rubella (MMR) · Varicella (VAR) · Hepatitis A (HepA) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9-16 yrs) · Mpox
Birth to 15 Months: 6 mos
Where CDC's chart changes category inside an age heading, a vaccine appears under each category and is marked as part of the age group.
Range of recommended ages for all children
- Respiratory syncytial virus
(RSV-mAb [Nirsevimab])1 dose depending on maternal RSV vaccination status, See Notes
CDC's chart shows this for part of this age group. - Hepatitis B
(HepB)←3rd dose→
- Rotavirus (RV)
RV1 (2-dose series); RV5 (3-dose series)See Notes
- Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs)3rd dose
- Haemophilus influenzae type b
(Hib)See Notes
- Pneumococcal conjugate
(PCV15, PCV20)3rd dose
- Inactivated poliovirus
(IPV)←3rd dose→
- Influenza (IIV3, ccIIV3)
1 or 2 doses annually
Range of recommended ages for certain high-risk groups or populations
- Respiratory syncytial virus
(RSV-mAb [Nirsevimab])CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group. - Measles, mumps, rubella
(MMR)See Notes
- Hepatitis A
(HepA)(See Notes)
- Meningococcal
(MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)See Notes
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Influenza (LAIV3) · Varicella (VAR) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9-16 yrs) · Mpox
Birth to 15 Months: 9 mos
Range of recommended ages for all children
- Hepatitis B
(HepB)←3rd dose→
- Inactivated poliovirus
(IPV)←3rd dose→
- Influenza (IIV3, ccIIV3)
1 or 2 doses annually
Range of recommended ages for catch-up vaccination
- Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Haemophilus influenzae type b
(Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Pneumococcal conjugate
(PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Respiratory syncytial virus
(RSV-mAb [Nirsevimab])1 dose (8 through 19 months), See Notes
- Measles, mumps, rubella
(MMR)See Notes
- Hepatitis A
(HepA)(See Notes)
- Meningococcal
(MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)See Notes
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Influenza (LAIV3) · Varicella (VAR) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9-16 yrs) · Mpox
Birth to 15 Months: 12 mos
Range of recommended ages for all children
- Hepatitis B
(HepB)←3rd dose→
- Haemophilus influenzae type b
(Hib)←3rd or 4th dose,
See Notes→ - Pneumococcal conjugate
(PCV15, PCV20)←4th dose→
- Inactivated poliovirus
(IPV)←3rd dose→
- Influenza (IIV3, ccIIV3)
1 or 2 doses annually
- Measles, mumps, rubella
(MMR)←1st dose→
- Varicella
(VAR)←1st dose→
- Hepatitis A
(HepA)←2-dose series, See Notes→
Range of recommended ages for catch-up vaccination
- Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Respiratory syncytial virus
(RSV-mAb [Nirsevimab])1 dose (8 through 19 months), See Notes
- Meningococcal
(MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)See Notes
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Influenza (LAIV3) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9-16 yrs) · Mpox
Birth to 15 Months: 15 mos
Range of recommended ages for all children
- Hepatitis B
(HepB)←3rd dose→
- Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs)←4th dose→
- Haemophilus influenzae type b
(Hib)←3rd or 4th dose,
See Notes→ - Pneumococcal conjugate
(PCV15, PCV20)←4th dose→
- Inactivated poliovirus
(IPV)←3rd dose→
- Influenza (IIV3, ccIIV3)
1 or 2 doses annually
- Measles, mumps, rubella
(MMR)←1st dose→
- Varicella
(VAR)←1st dose→
- Hepatitis A
(HepA)←2-dose series, See Notes→
Range of recommended ages for certain high-risk groups or populations
- Respiratory syncytial virus
(RSV-mAb [Nirsevimab])1 dose (8 through 19 months), See Notes
- Meningococcal
(MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)See Notes
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Influenza (LAIV3) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9-16 yrs) · Mpox
18 Months to 18 Years: 18 mos
Range of recommended ages for all children
- Hepatitis B (HepB)
←3rd dose→
- Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs)←4th dose→
- Inactivated poliovirus
(IPV)←3rd dose→
- Influenza (IIV3, ccIIV3)
1 or 2 doses annually
- Hepatitis A (HepA)
← 2-dose series, See Notes→
Range of recommended ages for catch-up vaccination
- Haemophilus influenzae type b (Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Pneumococcal conjugate (PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Measles, mumps, rubella (MMR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Varicella (VAR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Respiratory syncytial virus (RSV-mAb [Nirsevimab])
1 dose (8 through 19 months), See Notes
- Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)
See Notes
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Influenza (LAIV3) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9–16 yrs) · Mpox
18 Months to 18 Years: 19-23 mos
Where CDC's chart changes category inside an age heading, a vaccine appears under each category and is marked as part of the age group.
Range of recommended ages for all children
- Influenza (IIV3, ccIIV3)
1 or 2 doses annually
- Hepatitis A (HepA)
← 2-dose series, See Notes→
Range of recommended ages for catch-up vaccination
- Hepatitis B (HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Haemophilus influenzae type b (Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Pneumococcal conjugate (PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Inactivated poliovirus
(IPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Measles, mumps, rubella (MMR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Varicella (VAR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Respiratory syncytial virus (RSV-mAb [Nirsevimab])CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
- Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)
See Notes
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Respiratory syncytial virus (RSV-mAb [Nirsevimab]) · Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Influenza (LAIV3) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9–16 yrs) · Mpox
18 Months to 18 Years: 2-3 yrs
Range of recommended ages for all children
Range of recommended ages for catch-up vaccination
- Hepatitis B (HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Haemophilus influenzae type b (Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Pneumococcal conjugate (PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Inactivated poliovirus
(IPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Measles, mumps, rubella (MMR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Varicella (VAR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Hepatitis A (HepA)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)
See Notes
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Respiratory syncytial virus (RSV-mAb [Nirsevimab]) · Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9–16 yrs) · Mpox
18 Months to 18 Years: 4-6 yrs
Where CDC's chart changes category inside an age heading, a vaccine appears under each category and is marked as part of the age group.
Range of recommended ages for all children
- Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs)5th dose
- Inactivated poliovirus
(IPV)4th dose
- Influenza (IIV3, ccIIV3)
1 or 2 doses annually
- Influenza (LAIV3)
1 or 2 doses annually
- Measles, mumps, rubella (MMR)
2nd dose
- Varicella (VAR)
2nd dose
Range of recommended ages for catch-up vaccination
- Hepatitis B (HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Haemophilus influenzae type b (Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
- Pneumococcal conjugate (PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
- Hepatitis A (HepA)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Haemophilus influenzae type b (Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
- Pneumococcal conjugate (PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
- Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)
See Notes
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Respiratory syncytial virus (RSV-mAb [Nirsevimab]) · Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9–16 yrs) · Mpox
18 Months to 18 Years: 7-10 yrs
Where CDC's chart changes category inside an age heading, a vaccine appears under each category and is marked as part of the age group.
Range of recommended ages for all children
Range of recommended ages for catch-up vaccination
- Hepatitis B (HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Inactivated poliovirus
(IPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Measles, mumps, rubella (MMR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Varicella (VAR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Hepatitis A (HepA)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Haemophilus influenzae type b (Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Pneumococcal conjugate (PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Human papillomavirus (HPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
- Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)
See Notes
- Meningococcal B (MenB-4C, MenB-FHbp)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
- Dengue (DEN4CYD: 9–16 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
Recommended vaccination can begin in this age group
- Human papillomavirus (HPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Respiratory syncytial virus (RSV-mAb [Nirsevimab]) · Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) · Human papillomavirus (HPV) · Meningococcal B (MenB-4C, MenB-FHbp) · Respiratory syncytial virus vaccine (RSV [Abrysvo]) · Dengue (DEN4CYD: 9–16 yrs) · Mpox
18 Months to 18 Years: 11-12 yrs
Where CDC's chart changes category inside an age heading, a vaccine appears under each category and is marked as part of the age group.
Range of recommended ages for all children
- Influenza (IIV3, ccIIV3)
1 dose annually
- Influenza (LAIV3)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
- Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)
1 dose
- Human papillomavirus (HPV)
See Notes
- Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)
1st dose
Range of recommended ages for catch-up vaccination
- Hepatitis B (HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Inactivated poliovirus
(IPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Measles, mumps, rubella (MMR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Varicella (VAR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Hepatitis A (HepA)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Haemophilus influenzae type b (Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Pneumococcal conjugate (PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Meningococcal B (MenB-4C, MenB-FHbp)
See Notes
- Respiratory syncytial virus vaccine (RSV [Abrysvo])
Seasonal administration during pregnancy, See Notes
- Dengue (DEN4CYD: 9–16 yrs)
Seropositive in endemic dengue areas (See Notes)
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Respiratory syncytial virus (RSV-mAb [Nirsevimab]) · Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) · Meningococcal B (MenB-4C, MenB-FHbp) · Mpox
18 Months to 18 Years: 13-15 yrs
Range of recommended ages for all children
Range of recommended ages for catch-up vaccination
- Hepatitis B (HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Inactivated poliovirus
(IPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Measles, mumps, rubella (MMR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Varicella (VAR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Hepatitis A (HepA)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Human papillomavirus (HPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Haemophilus influenzae type b (Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Pneumococcal conjugate (PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Meningococcal B (MenB-4C, MenB-FHbp)
See Notes
- Respiratory syncytial virus vaccine (RSV [Abrysvo])
Seasonal administration during pregnancy, See Notes
- Dengue (DEN4CYD: 9–16 yrs)
Seropositive in endemic dengue areas (See Notes)
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19
No Guidance/Not Applicable
Respiratory syncytial virus (RSV-mAb [Nirsevimab]) · Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) · Meningococcal B (MenB-4C, MenB-FHbp) · Mpox
18 Months to 18 Years: 16 yrs
Range of recommended ages for all children
- Influenza (IIV3, ccIIV3)
1 dose annually
- Influenza (LAIV3)
1 dose annually
- Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)
2nd dose
Range of recommended ages for catch-up vaccination
- Hepatitis B (HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Inactivated poliovirus
(IPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine. - Measles, mumps, rubella (MMR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Varicella (VAR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Hepatitis A (HepA)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Human papillomavirus (HPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Haemophilus influenzae type b (Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Pneumococcal conjugate (PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Meningococcal B (MenB-4C, MenB-FHbp)
See Notes
- Respiratory syncytial virus vaccine (RSV [Abrysvo])
Seasonal administration during pregnancy, See Notes
- Dengue (DEN4CYD: 9–16 yrs)
Seropositive in endemic dengue areas (See Notes)
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19 - Meningococcal B (MenB-4C, MenB-FHbp)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
No Guidance/Not Applicable
Respiratory syncytial virus (RSV-mAb [Nirsevimab]) · Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) · Mpox
18 Months to 18 Years: 17-18 yrs
Where CDC's chart changes category inside an age heading, a vaccine appears under each category and is marked as part of the age group.
Range of recommended ages for all children
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19 - Influenza (IIV3, ccIIV3)
1 dose annually
- Influenza (LAIV3)
1 dose annually
Range of recommended ages for catch-up vaccination
- Hepatitis B (HepB)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Inactivated poliovirus
(IPV)See Notes
CDC's chart shows this for part of this age group. - Measles, mumps, rubella (MMR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Varicella (VAR)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Hepatitis A (HepA)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Human papillomavirus (HPV)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
Range of recommended ages for certain high-risk groups or populations
- Haemophilus influenzae type b (Hib)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Pneumococcal conjugate (PCV15, PCV20)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
- Meningococcal B (MenB-4C, MenB-FHbp)
See Notes
- Respiratory syncytial virus vaccine (RSV [Abrysvo])
Seasonal administration during pregnancy, See Notes
- MpoxCDC's chart shows this category here without further text; see CDC's notes for this vaccine.CDC's chart shows this for part of this age group.
Vaccination is based on shared clinical decision making
- COVID-19
(1vCOV-mRNA, 1vCOV-aPS)See Notes
CDC's chart shows this for part of this age group.RxEvidence note: CDC's child and adolescent schedule notes (addendum updated July 2, 2025) give COVID-19 dosing for 2024–25 vaccines. CDC's COVID-19 page for health care providers (updated October 7, 2026) refers to 2026–2027 COVID-19 vaccines. These two CDC pages differ; open both. CDC's COVID-19 page for health care providers CDC's schedule note on COVID-19 - Meningococcal B (MenB-4C, MenB-FHbp)CDC's chart shows this category here without further text; see CDC's notes for this vaccine.
No Guidance/Not Applicable
Respiratory syncytial virus (RSV-mAb [Nirsevimab]) · Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) · Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) · Dengue (DEN4CYD: 9–16 yrs) · Mpox
About this view
Each entry is CDC's own cell text from its child and adolescent schedule, regrouped by age heading; the headings are CDC's own legend wording. RxEvidence has not added, removed or reworded schedule content. Read it with CDC's notes, which hold dose intervals, catch-up rules and conditions. Source: CDC, child and adolescent schedule by age. The same tables as CDC draws them, with every age side by side, are folded below.
The re-check date means this copy was compared with CDC's live page and was identical; it does not mean CDC's page is current for every product or season. The American Academy of Pediatrics publishes its own child and adolescent schedule, which can differ; both are listed in the source directory.
Show CDC's full child and adolescent charts, all ages side by side (scrolls sideways)
Child and adolescent immunization schedule by age
Source: CDC, Child and adolescent immunization schedule by age. Each cell is CDC's own wording. CDC's page shows: addendum updated July 2, 2025; page last updated July 2, 2025. Re-checked against CDC's live page on 12 Oct 2026: the tables are identical. These tables must be read with CDC's notes, which hold the dose intervals and catch-up rules. A vaccine's name links to CDC's notes for it.
- Range of recommended ages for all children
- Range of recommended ages for catch-up vaccination
- Range of recommended ages for certain high-risk groups or populations
- Recommended vaccination can begin in this age group
- Vaccination is based on shared clinical decision making
- No Guidance/Not Applicable
Scroll sideways to see every age. Colour is never the only signal: hover or focus a cell for CDC's wording of what it means.
Birth to 15 Months
| Vaccine and other immunizing agents | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory syncytial virus (RSV-mAb [Nirsevimab]) | 1 dose depending on maternal RSV vaccination status, See Notes | Range of recommended ages for all children | Range of recommended ages for all children | Range of recommended ages for certain high-risk groups or populations | 1 dose (8 through 19 months), See Notes | ||||||
| Hepatitis B (HepB) | 1st dose | ←2nd dose→ | Range of recommended ages for catch-up vaccination | ←3rd dose→ | |||||||
| Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) | No Guidance/Not Applicable | 1st dose | 2nd dose | See Notes | No Guidance/Not Applicable | ||||||
| Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) | No Guidance/Not Applicable | 1st dose | 2nd dose | 3rd dose | Range of recommended ages for catch-up vaccination | ←4th dose→ | |||||
| Haemophilus influenzae type b (Hib) | No Guidance/Not Applicable | 1st dose | 2nd dose | See Notes | Range of recommended ages for catch-up vaccination | ←3rd or 4th dose, See Notes→ | |||||
| Pneumococcal conjugate (PCV15, PCV20) | No Guidance/Not Applicable | 1st dose | 2nd dose | 3rd dose | Range of recommended ages for catch-up vaccination | ←4th dose→ | |||||
| Inactivated poliovirus (IPV) | No Guidance/Not Applicable | 1st dose | 2nd dose | ←3rd dose→ | |||||||
| COVID-19 (1vCOV-mRNA, 1vCOV-aPS) | No Guidance/Not Applicable | See Notes | |||||||||
| Influenza (IIV3, ccIIV3) | No Guidance/Not Applicable | 1 or 2 doses annually | |||||||||
| Influenza (LAIV3) | No Guidance/Not Applicable | ||||||||||
| Measles, mumps, rubella (MMR) | No Guidance/Not Applicable | See Notes | ←1st dose→ | ||||||||
| Varicella (VAR) | No Guidance/Not Applicable | ←1st dose→ | |||||||||
| Hepatitis A (HepA) | No Guidance/Not Applicable | (See Notes) | ←2-dose series, See Notes→ | ||||||||
| Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) | No Guidance/Not Applicable | ||||||||||
| Human papillomavirus (HPV) | No Guidance/Not Applicable | ||||||||||
| Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) | No Guidance/Not Applicable | See Notes | |||||||||
| Meningococcal B (MenB-4C, MenB-FHbp) | No Guidance/Not Applicable | ||||||||||
| Respiratory syncytial virus vaccine (RSV [Abrysvo]) | No Guidance/Not Applicable | ||||||||||
| Dengue (DEN4CYD: 9-16 yrs) | No Guidance/Not Applicable | ||||||||||
| Mpox | No Guidance/Not Applicable | ||||||||||
18 Months to 18 Years
| Vaccine and other immunizing agents | 18 mos | 19-23 mos | 2-3 yrs | 4-6 yrs | 7-10 yrs | 11-12 yrs | 13-15 yrs | 16 yrs | 17-18 yrs | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory syncytial virus (RSV-mAb [Nirsevimab]) | 1 dose (8 through 19 months), See Notes | Range of recommended ages for certain high-risk groups or populations | No Guidance/Not Applicable | No Guidance/Not Applicable | No Guidance/Not Applicable | No Guidance/Not Applicable | |||||||||||||||||||||
| Hepatitis B (HepB) | ←3rd dose→ | Range of recommended ages for catch-up vaccination | |||||||||||||||||||||||||
| Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) | No Guidance/Not Applicable | ||||||||||||||||||||||||||
| Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) | ←4th dose→ | Range of recommended ages for catch-up vaccination | 5th dose | No Guidance/Not Applicable | |||||||||||||||||||||||
| Haemophilus influenzae type b (Hib) | Range of recommended ages for catch-up vaccination | Range of recommended ages for catch-up vaccination | Range of recommended ages for certain high-risk groups or populations | Range of recommended ages for certain high-risk groups or populations | |||||||||||||||||||||||
| Pneumococcal conjugate (PCV15, PCV20) | Range of recommended ages for catch-up vaccination | Range of recommended ages for catch-up vaccination | Range of recommended ages for certain high-risk groups or populations | Range of recommended ages for certain high-risk groups or populations | |||||||||||||||||||||||
| Inactivated poliovirus (IPV) | ←3rd dose→ | Range of recommended ages for catch-up vaccination | 4th dose | Range of recommended ages for catch-up vaccination | Range of recommended ages for catch-up vaccination | Range of recommended ages for catch-up vaccination | See Notes | ||||||||||||||||||||
| COVID-19 (1vCOV-mRNA, 1vCOV-aPS) | See Notes | Shared clinical decision making | Range of recommended ages for all children | Range of recommended ages for all children | |||||||||||||||||||||||
| Influenza (IIV3, ccIIV3) | 1 or 2 doses annually | Range of recommended ages for all children | Range of recommended ages for all children | Range of recommended ages for all children | Range of recommended ages for all children | 1 dose annually | |||||||||||||||||||||
| Influenza (LAIV3) | No Guidance/Not Applicable | 1 or 2 doses annually | Range of recommended ages for all children | Range of recommended ages for all children | Range of recommended ages for all children | Range of recommended ages for all children | Range of recommended ages for all children | Range of recommended ages for all children | 1 dose annually | ||||||||||||||||||
| Measles, mumps, rubella (MMR) | Range of recommended ages for catch-up vaccination | 2nd dose | Range of recommended ages for catch-up vaccination | ||||||||||||||||||||||||
| Varicella (VAR) | Range of recommended ages for catch-up vaccination | 2nd dose | Range of recommended ages for catch-up vaccination | ||||||||||||||||||||||||
| Hepatitis A (HepA) | ← 2-dose series, See Notes→ | Range of recommended ages for catch-up vaccination | |||||||||||||||||||||||||
| Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) | No Guidance/Not Applicable | Range of recommended ages for catch-up vaccination | 1 dose | Range of recommended ages for certain high-risk groups | |||||||||||||||||||||||
| Range of recommended ages for catch-up vaccination | |||||||||||||||||||||||||||
| Human papillomavirus (HPV) | No Guidance/Not Applicable | Range of recommended ages for certain high-risk groups | See Notes | Range of recommended ages for catch-up vaccination | |||||||||||||||||||||||
| Range of recommended ages for certain high-risk groups | |||||||||||||||||||||||||||
| Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) | See Notes | 1st dose | Range of recommended ages for catch-up vaccination | 2nd dose | Range of recommended ages for catch-up vaccination | ||||||||||||||||||||||
| Meningococcal B (MenB-4C, MenB-FHbp) | No Guidance/Not Applicable | No Guidance/Not Applicable | No Guidance/Not Applicable | No Guidance/Not Applicable | No Guidance/Not Applicable | Range of recommended ages for certain high-risk groups or populations | See Notes | ||||||||||||||||||||
| No Guidance/Not Applicable | No Guidance/Not Applicable | Vaccination is based on shared clinical decision making | |||||||||||||||||||||||||
| Respiratory syncytial virus vaccine (RSV [Abrysvo]) | No Guidance/Not Applicable | Seasonal administration during pregnancy, See Notes | |||||||||||||||||||||||||
| Dengue (DEN4CYD: 9–16 yrs) | No Guidance/Not Applicable | No Guidance/Not Applicable | No Guidance/Not Applicable | Range of recommended ages for certain high-risk groups or populations | Seropositive in endemic dengue areas (See Notes) | No Guidance/Not Applicable | |||||||||||||||||||||
| Mpox | No Guidance/Not Applicable | Range of recommended ages for certain high-risk groups or populations | |||||||||||||||||||||||||
Source: Centers for Disease Control and Prevention (CDC). This material is copied from CDC's website, which offers it at no charge, and is shown as CDC wrote it. RxEvidence is not affiliated with CDC, the Department of Health and Human Services, or the U.S. Government, and this use does not imply their endorsement of RxEvidence or any product, service or organization. Reference to specific commercial products, manufacturers, companies, or trademarks does not constitute its endorsement or recommendation by the U.S. Government, Department of Health and Human Services, or Centers for Disease Control and Prevention. CDC revises these pages; CDC's page is the authority and takes precedence over this copy.
